success
vivo
infect
follow
pathogen
entri
requir
evas
subvers
multipl
immunolog
barrier
antimicrobi
peptid
amp
one
first
immun
pathway
upregul
infect
multipl
pathogen
multipl
organ
vivo
human
mani
class
amp
exhibit
broad
antimicrobi
activ
defensin
human
cathelicidin
best
studi
exampl
wherea
histor
efficaci
therapeut
potenti
amp
bacteri
infect
primari
focu
research
recent
studi
begun
elucid
antivir
properti
amp
well
role
regul
inflamm
chemoattract
amp
therapeut
tool
seem
especi
promis
emerg
infecti
viral
pathogen
approv
vaccin
treatment
current
avail
dengu
viru
denv
zika
viru
zikv
review
summar
recent
studi
elucid
efficaci
divers
mechan
action
variou
class
amp
multipl
viral
pathogen
well
potenti
use
human
amp
novel
antivir
therapeut
strategi
found
virtual
organ
antimicrobi
peptid
amp
short
positivelycharg
oligopeptid
exhibit
divers
structur
function
amp
fundament
compon
innat
immun
system
play
vital
role
initi
immun
respons
gener
injuri
infect
ampmedi
immun
respons
rapidli
activ
follow
infect
amp
primarili
synthes
store
cell
myeloid
origin
epitheli
cell
among
first
respond
infect
amp
express
wide
varieti
tissu
includ
skin
eye
oral
caviti
ear
airway
lung
femal
reproduct
tract
cervicalvagin
fluid
intestin
urinari
tract
major
amp
synthes
larg
polyprotein
precursor
proteolyt
process
releas
activ
peptid
segment
present
alon
multipl
copi
remov
signal
peptid
may
posttransl
cotransl
process
process
function
peptid
character
mani
class
mammal
human
includ
defensin
cathelicidin
transferrin
hepcidin
human
antimicrobi
protein
dermcidin
histon
amp
deriv
known
protein
chemokin
amp
immun
cell
antimicrobi
neuropeptid
betaamyloid
peptid
amp
class
shown
possess
antimicrobi
activ
class
demonstr
antivir
properti
defin
featur
amp
rapid
respons
infect
bacteria
virus
fungi
protozoa
exhibit
inhibitori
immunomodulatori
properti
amp
intens
studi
altern
antibiot
bacteri
infect
recent
year
gain
substanti
attent
viral
therapeut
report
applic
human
amp
treatment
viral
infect
highli
abund
wide
distribut
defensin
modul
immun
respons
therebi
play
central
role
innat
immun
defensin
classifi
three
subgroup
although
human
produc
function
member
famili
amp
express
mrna
observ
human
mrna
contain
prematur
stop
codon
prevent
translat
howev
function
present
nonhuman
primat
date
six
peptid
identifi
variou
speci
origin
isol
neutrophil
four
six
distinct
term
human
neutrophil
peptid
also
produc
myeloidlineag
cell
macrophag
natur
killer
nk
cell
class
bcell
express
epitheli
cell
small
intestin
famili
amp
commonli
express
bird
mammal
human
three
fulli
character
fourth
recent
identifi
primarili
express
epitheli
cell
keratinocyt
also
produc
neutrophil
macrophag
mast
cell
nk
cell
dendrit
cell
lymphocyt
current
data
suggest
function
redund
compar
efficaci
defensin
variou
pathogen
defensin
defin
presenc
conserv
space
pattern
compris
cystein
residu
critic
efficaci
cation
antimicrobi
properti
human
compos
amino
acid
overal
posit
charg
defensin
exhibit
characterist
structur
distinct
sixcystein
motif
stabil
consequ
presenc
three
intramolecular
disulfid
bond
synthes
prepropeptid
consist
ntermin
signal
sequenc
anion
propeptid
ctermin
matur
peptid
compris
approxim
amino
acid
synthes
promyelocyt
store
primari
neutrophil
granul
matur
peptid
contrast
short
ntermin
proregion
retain
antimicrobi
activ
fulllength
form
therefor
requir
ntermin
process
fulli
activ
synthes
epitheli
compart
rang
amino
acid
length
antivir
activ
defensin
first
report
sinc
defensin
demonstr
protect
human
immunodefici
viru
hiv
influenza
viru
iav
human
adenoviru
hadv
sever
acut
respiratori
syndrom
coronaviru
sarsc
papillomaviru
hpv
respiratori
syncyti
viru
rsv
herp
simplex
viru
hsv
recent
studi
focus
elucid
multipl
mechan
associ
defensin
antivir
activ
tabl
defensin
block
viral
infect
direct
action
viru
particl
interfer
indirectli
variou
stage
viral
life
cycl
avail
data
suggest
antivir
activ
occur
predominantli
viral
entri
step
howev
antivir
effect
stage
infect
also
report
particularli
affect
viral
traffick
within
infect
cell
defensin
also
modifi
innat
immun
respons
viral
infect
includ
modul
tcell
macrophag
dendrit
cell
recruit
site
infect
wound
heal
angiogenesi
differenti
matur
dendrit
cell
induct
product
proinflammatori
cytokin
macrophag
mast
cell
keratinocyt
regul
cell
death
pathway
exampl
suppress
activ
caspas
cascad
prevent
apoptosi
infect
cell
similarli
concentr
hnp
releas
microenviron
upon
activ
neutrophil
inflamm
exert
differenti
effect
cytokin
product
activ
monocyt
hnp
concentr
nm
upregul
express
tumor
necrosi
factor
wherea
concentr
cytotox
monocyt
human
adenoviru
hadv
nonenvelop
doublestrand
dna
viru
capabl
infect
respiratori
gastrointestin
ocular
excretori
system
human
approxim
recogn
hadv
serotyp
subdivid
speci
ag
current
limit
number
hadv
therapeut
strategi
vaccin
avail
treat
hadv
infect
alpha
defensin
demonstr
abil
hinder
hadv
infect
vitro
reduc
hadv
replic
cell
expos
peptid
ic
prior
infect
peptid
ad
min
post
inocul
suggest
inhibit
occur
earli
stage
viral
infect
addit
studi
shown
direct
bind
hadv
particl
prior
infect
prevent
releas
intern
viral
particl
endosom
subsequ
viral
particl
appear
coloc
lysosom
indic
alter
viral
traffick
follow
infect
consequ
bind
find
suggest
defensin
antivir
activ
hadv
result
blockag
hadv
uncoat
genom
exposur
addit
antivir
activ
speci
specif
pretreat
decreas
hadv
infect
subspeci
ac
e
infect
hadv
subspeci
f
demonstr
chang
caus
speci
specif
activ
yet
determin
earli
infiltr
influenza
viru
iav
neutrophil
predomin
infect
airway
highlight
import
initi
immun
respons
iav
defensin
thu
like
interact
iav
neutrophil
extracellular
trap
net
display
hnp
form
vivo
vitro
respons
iav
infect
cell
incub
defensin
preor
postinfect
demonstr
minim
inhibitori
activ
iav
wherea
incub
hnp
virion
prior
infect
necessari
antivir
activ
amp
iav
eg
ic
addit
bind
activ
defensin
iav
increas
format
multimolecular
assembl
defensin
may
respons
pore
format
iav
envelop
therebi
destabil
virion
prior
receptor
bind
cellular
entri
express
report
variou
epitheli
cell
tissu
demonstr
uniqu
express
induct
profil
respons
iav
infect
howev
also
detect
monocyt
macrophag
monocytederiv
dendrit
cell
dc
possess
strong
neutral
activ
multipl
iav
strain
hbd
exhibit
low
potenc
direct
inhibitor
iav
virion
specul
play
import
immunomodulatori
role
limit
inflamm
iav
infect
exact
sequenc
immunomodulatori
event
yet
determin
report
delet
analog
mice
result
seriou
inflammatori
reaction
iav
addit
demonstr
strong
antiinflammatori
effect
cell
stimul
ngml
lipopolysaccharid
lp
confirm
inhibit
express
inflammatori
mediat
convers
inhibit
iav
replic
infect
cell
preincub
virion
capabl
reduc
replic
iav
strain
multipl
cell
line
compar
replic
untreat
cell
similarli
reduc
infecti
viru
strain
iav
variou
cell
line
defensin
demonstr
antivir
activ
human
immunodefici
viru
hiv
mediat
direct
viruspeptid
interact
andor
inhibit
viral
genom
replic
inhibit
mediat
direct
bind
defensin
hiv
virion
attribut
interact
positivelycharg
hnp
negativelycharg
moieti
hiv
envelop
glycoprotein
function
lectin
directli
block
interact
hiv
receptor
howev
exact
mechan
interact
well
character
also
interfer
critic
step
hiv
replic
cycl
inhibit
protein
kinas
c
signal
import
transcript
nuclear
import
hiv
genom
exhibit
robust
dosedepend
ic
nm
suppress
replic
absenc
serum
preincub
virion
also
block
infect
step
prior
viral
entri
competit
bind
receptor
dosedepend
manner
hiv
therebi
block
hiv
entri
target
cell
interestingli
contrast
interact
hiv
inhibit
hiv
replic
greater
effect
unclear
whether
efficaci
mediat
direct
effect
virion
also
host
process
ultim
affect
viral
replic
also
exert
antivir
activ
hiv
express
induc
microbi
product
endotoxin
virus
bacteria
proinflammatori
cytokin
tnf
express
mrna
induc
hiv
human
oral
epitheli
cell
inhibit
format
earli
hiv
transcript
product
affect
cellcel
fusion
alpha
exhibit
antihsv
properti
inhibit
hsv
bind
target
receptor
directli
interact
either
hsv
glycoprotein
bind
heparan
sulfat
hs
therebi
prevent
viral
entri
bind
either
hsv
receptor
hsv
glycoprotein
therebi
elicit
stronger
inhibit
viral
entri
furthermor
treatment
infect
cell
defensin
postinfect
result
substanti
reduct
viral
replic
indic
peptid
exhibit
post
entri
antivir
effect
addit
studi
explor
demonstr
abil
reduc
intracellular
hsv
protein
transport
express
infect
exhibit
greatest
antivir
potenti
hsv
reduc
hsv
titer
upon
combin
preand
posttreat
infect
cell
compar
reduc
titer
follow
treatment
antivir
effect
human
defensin
rsv
rel
unexplor
studi
assess
leukotrien
stimul
nasal
neutrophil
activ
highlight
possibl
sourc
antivir
activ
rsv
cell
pretreat
reduc
rsv
viral
titer
follow
infect
electron
microscopi
imag
reveal
damag
lipid
envelop
rsv
follow
treatment
suggest
defensin
destabil
rsv
virion
envelop
therebi
inhibit
viral
cellular
entri
use
defensin
antirsv
therapi
may
also
limit
viral
evolutionari
strategi
counter
antivir
activ
due
difficulti
chang
viral
envelop
lipid
composit
evolutionari
longev
defensin
suggest
favor
strategi
make
defensin
attract
therapeut
candid
treatment
rsv
infect
possess
level
antihuman
papilloma
viru
hpv
activ
notabl
except
due
low
toxic
high
efficaci
frequent
test
antihpv
candid
recent
studi
focus
sole
secret
epitheli
cell
genitourinari
tract
antivir
activ
hpv
timeindepend
robust
inhibit
even
peptid
introduc
cell
six
hour
post
infect
vitro
employ
immunofluoresc
confoc
microscopi
author
demonstr
peptid
inhibit
viral
entri
rather
prevent
virion
escap
cytoplasm
vesicl
cours
hpv
entri
cleavag
hpv
capsid
protein
furin
cellular
proteas
requir
success
infect
directli
disrupt
proteolyt
process
step
therebi
prevent
hpv
genom
escap
endosom
interestingli
use
furincleav
hpv
result
abrog
activ
still
block
hpv
infect
prevent
viral
capsid
dissoci
genom
reduc
viral
traffick
within
host
cell
result
indic
particularli
demonstr
robust
antihpv
activ
target
multipl
step
viral
life
cycl
cathelicidin
peptid
conserv
cathelin
domain
protein
sequenc
first
identifi
porcin
leukocyt
capabl
inhibit
proteas
cathepsinl
cathelicidin
typic
linear
peptid
fold
amphipath
structur
frequent
cleav
highli
variabl
ctermin
antimicrobi
domain
human
cathelicidin
produc
vitamin
ddepend
antimicrobi
pathway
although
multipl
cathelicidin
found
natur
human
express
singl
cathelicidin
known
human
cation
antimicrobi
peptid
identifi
isol
neutrophil
like
cathelicidin
synthes
prepropeptid
follow
proteolyt
remov
signal
peptid
inact
propeptid
tag
storag
neutrophil
granul
activ
cation
molecul
gener
cleavag
cterminu
end
precursor
protein
yield
linear
peptid
name
allud
molecular
weight
polypeptid
kda
cation
charact
structur
wherea
refer
amino
acid
length
peptid
along
leuleu
motif
locat
nterminu
peptid
also
produc
epitheli
cell
may
play
import
role
initi
immun
respons
variou
pathogen
epitheli
skin
cell
cleav
shorter
segment
exhibit
potent
antimicrobi
activ
also
produc
monocyt
nk
cell
mast
cell
b
cell
colon
enterocyt
keratinocyt
detect
numer
tissu
biolog
fluid
sweat
breast
milk
wound
fluid
vernix
tracheal
aspir
newborn
semin
plasma
concentr
precursor
tissu
bodi
fluid
rang
howev
concentr
increas
infect
bronchoalveolar
fluid
nasal
secret
concentr
vari
express
regul
number
endogen
factor
includ
proinflammatori
cytokin
growth
factor
activ
form
vitamin
function
chemoattract
neutrophil
monocyt
dendrit
tcell
rapidli
releas
epitheli
cell
leukocyt
follow
infect
stimul
product
human
dendrit
cell
may
act
anti
proinflammatori
factor
immun
respons
variou
infect
individu
cathelicidin
defici
neutrophil
display
increas
suscept
infect
antivir
activ
report
number
virus
includ
iav
rsv
rhinoviru
hrv
vaccinia
viru
vacv
hsv
zikv
hepat
c
viru
hcv
mediat
primarili
interact
viru
outer
envelop
tabl
propos
remov
outer
membran
virus
singl
event
antimicrobi
attack
rather
gradual
piecebypiec
remov
suggest
carpet
model
antimicrobi
peptid
action
wherein
suscept
membran
remain
intact
threshold
concentr
peptid
reach
follow
rapid
disintegr
target
membran
occur
therapeut
activ
influenza
type
viru
demonstr
vivo
vitro
like
vivo
iav
encount
respiratori
tract
follow
innat
immun
respons
viru
secret
neutrophil
macrophag
epitheli
cell
earli
studi
assess
antivir
activ
vivo
use
mous
iav
strain
mice
nebul
day
prior
infect
lethal
dose
iva
mous
strain
surviv
weight
loss
monitor
day
follow
infect
initi
mice
exhibit
weight
loss
weight
loss
ceas
day
seven
mice
treat
iav
antivir
zanamivir
mice
treat
zanamivir
exhibit
surviv
compar
untreat
group
succumb
infect
day
nine
suggest
therapeut
use
reduc
iav
infect
sever
manner
compar
zanamivir
also
decreas
express
inflammatori
cytokin
particularli
granulocytemacrophag
colonystimul
factor
gmcsf
keratinocyt
chemoattract
kc
chemotact
cytokin
known
regul
activ
normal
tcell
express
secret
rant
bronchoalveolar
lavag
fluid
mice
infect
two
day
follow
treatment
determin
immunoassay
demonstr
immunomodulatori
properti
vitro
plaqu
assay
demonstr
one
log
inhibit
viru
preincub
madindarbi
canin
kidney
mdck
cell
iav
infect
vitro
treatment
prevent
viral
uptak
caus
viral
aggreg
associ
block
hemagglutinin
ha
interestingli
inhibit
iav
replic
postentri
step
prior
viral
rna
protein
synthesi
reduct
viral
load
direct
antivir
effect
epitheli
cell
inflammatori
cytokin
product
link
activ
inhibit
strain
iav
signific
reduct
uptak
viru
cell
manner
depend
dosag
optim
antiiav
activ
central
helix
requir
evid
fragment
contain
complet
central
sequenc
peptid
demonstr
robust
antivir
respons
compar
fragment
shorter
central
fragment
concentr
partial
inhibit
howev
inhibit
surprisingli
lost
higher
concentr
strain
contain
pandem
ha
mex
howev
inhibit
concentr
test
consist
previou
studi
result
suggest
antivir
effect
determin
direct
interact
viral
ha
experiment
data
also
demonstr
particip
host
defens
iav
modul
innat
immun
cell
particularli
neutrophil
iav
infect
induc
respiratori
burst
respons
neutrophil
respons
notic
upregul
preincub
iav
alon
stimul
respiratori
burst
respons
howev
optim
enhanc
antivir
respons
achiev
viru
preincub
furthermor
grow
evid
net
format
play
import
role
iav
infect
recent
vivo
studi
provid
evid
net
format
lung
iavinfect
mice
hand
vitro
evid
bind
iva
net
suggest
induc
increas
net
format
respons
iav
may
promot
viral
clearanc
vivo
data
also
suggest
signific
protect
iav
may
provid
therapeut
treatment
influenza
infect
individu
increas
natur
cathelicidin
express
iavinfect
lung
henc
maxim
antiiav
function
approach
therapeut
administr
naturallyoccur
cathelicidin
well
increas
vitamin
level
boost
endogen
cathelicidin
propos
earlier
studi
provid
evid
abil
protect
infect
given
epitheli
express
includ
peripher
blood
mononuclear
cell
tcell
vitro
directli
inhibit
activ
revers
transcriptas
via
proteinprotein
interact
dosedepend
manner
ic
inhibit
proteas
activ
also
report
howev
activ
less
potent
compar
inhibit
revers
transcriptas
inhibit
addit
plasma
level
hiv
posit
individu
undergo
antiretrovir
therapi
art
much
higher
patient
correspond
increas
suscept
secondari
infect
patient
undergo
art
date
littl
research
perform
character
antivir
activ
denv
howev
recent
studi
demonstr
treatment
dengu
viru
inhibit
viral
infect
green
monkey
kidney
vero
cell
incub
viru
prior
infect
inhibit
product
viral
particl
wherea
pretreat
cell
demonstr
effect
viral
replic
molecular
dock
studi
e
protein
reveal
direct
bind
protein
moieti
demonstr
peptid
abil
act
entri
inhibitor
recent
studi
assess
truncat
full
length
variant
serotyp
denv
reveal
inhibitori
properti
requir
full
length
peptid
comparison
requir
higher
concentr
inhibit
effect
potent
former
inhibit
howev
promin
lower
concentr
recent
studi
use
infect
keratinocyt
demonstr
product
amp
infect
cell
well
bystand
cell
preincub
cell
prior
infect
result
signific
decreas
viral
titer
replic
infect
keratinocyt
wherea
demonstr
minim
inhibit
addit
vitamin
induc
express
supplement
popul
vitamin
prior
denv
outbreak
season
suggest
possibl
prevent
strategi
control
viru
initi
stage
infect
studi
demonstr
efficaci
rsv
cell
preincub
protect
rsv
infect
wherea
addit
two
hour
postinfect
result
decreas
antivir
activ
addit
limit
viralinduc
cell
death
infect
cell
cultur
indic
peptid
activ
limit
prophylact
treatment
treatment
epitheli
cell
prior
infect
result
peptid
intern
retent
provid
antivir
protect
sever
hour
posttreat
furthermor
rsv
infect
induc
product
cytokin
chemokin
lung
impact
express
chemokin
well
viral
load
preincub
rsv
exact
mechan
antivir
activ
rsv
well
establish
specul
peptid
directli
interact
viru
prior
infect
due
dosedepend
earli
effect
rsv
infect
interestingli
children
lower
cathelicidin
level
suscept
rsv
infect
display
increas
sever
rsvassoci
bronchiti
human
rhinovirus
hrv
caus
agent
common
cold
viral
respiratori
tract
infect
respiratori
epitheli
cell
primari
target
hrv
infect
studi
evalu
efficaci
hrv
util
airway
epitheli
cell
demonstr
direct
antivir
activ
hrv
ad
pretreat
act
viral
particl
ad
post
infect
act
host
cell
induc
signific
reduct
metabol
activ
infect
cell
measur
mitochondri
metabol
potenti
studi
evalu
hrv
cystic
fibrosi
cell
reveal
express
decreas
hrv
viral
load
vivo
thu
reduc
hrv
infect
respiratori
cell
well
cystic
fibrosi
cell
vaccinia
viru
vacv
dna
viru
infect
mani
type
mammalian
cell
limit
vacv
replic
alter
viral
membran
vacv
gene
express
viral
titer
reduc
dosedepend
manner
cell
preincub
transmiss
electron
microscopi
imag
shown
disrupt
integr
vacv
viral
membran
h
incub
wherea
murin
demonstr
great
efficaci
protect
vacv
infect
efficaci
human
vacv
unknown
studi
evalu
efficaci
perform
assess
inhibit
context
corneal
infect
inhibit
infect
preincub
virion
vitro
reduc
viral
titer
corneal
epitheli
cell
compar
scrambl
control
anoth
studi
evalu
activ
corneal
implant
assess
releas
deliv
corneal
implantincorpor
nanoparticl
wherea
clear
virus
infect
cell
block
infect
corneal
epitheli
cell
prevent
viralcel
attach
studi
reinforc
mechan
antivir
activ
entri
inhibit
interestingli
releas
infect
keratinocyt
also
enhanc
infect
studi
measur
suscept
langerhan
cell
lc
implic
increas
cell
receptor
count
result
increas
infect
numer
studi
link
decreas
infect
consequ
defensin
treatment
differ
activ
amp
possibl
attribut
differ
cell
target
zika
viru
zikv
positivesens
singlestrand
rna
viru
caus
fever
headach
rash
joint
pain
myalgia
children
adult
microcephali
ventriculomegali
intracrani
calcif
abnorm
corpu
callosum
retin
lesion
craniofaci
disord
hear
loss
dysphagia
neonat
emerg
zikv
global
concern
sinc
first
major
infecti
diseas
associ
birth
defect
five
decad
current
vaccin
treatment
avail
prevent
zikv
infect
et
al
conduct
studi
determin
whether
synthet
deriv
use
treat
zikv
infect
primari
human
fetal
astrocyt
wherea
toxic
cell
ec
deriv
safe
use
due
lower
toxic
ec
treatment
primari
human
fetal
astrocyt
h
zikv
infect
result
sevenfold
decreas
number
zikv
plaqu
form
unit
preincub
zikv
h
result
least
decreas
number
activ
zika
virion
addit
possibl
directli
interact
zikv
virion
mechan
antivir
activ
increas
express
dosedepend
manner
impact
abil
zikv
infect
primari
human
fetal
astrocyt
studi
suggest
may
possibl
option
prevent
treatment
zikv
infect
hepat
c
viru
hcv
major
worldwid
health
concern
possibl
sever
outcom
includ
cirrhosi
liver
cancer
even
death
infect
left
untreat
wherea
effect
antivir
hcv
infect
exist
unmet
need
novel
antihcv
treatment
overcom
current
treatment
barrier
cost
access
healthcar
demonstr
antihcv
properti
cell
cultur
hcv
titer
significantli
reduc
hcv
preincub
subsequ
use
infect
cell
although
differ
strain
hcv
util
studi
antivir
effect
associ
depend
specif
hcv
strain
decreas
viral
replic
occur
dosedepend
manner
furthermor
primarili
act
hcv
extracellularli
consist
activ
envelop
virus
venezuelan
equin
enceph
viru
veev
alphaviru
categor
biothreat
agent
due
eas
aerosol
high
retent
infect
aerosol
form
current
fda
approv
therapeut
combat
veev
infect
recent
demonstr
antiveev
activ
vitro
signific
decreas
intracellular
veev
genom
rna
copi
observ
upon
preincub
veev
microscopi
data
reveal
extracellular
aggreg
veev
virion
suggest
mechan
action
veev
direct
interact
viral
particl
therebi
inhibit
entri
pretreat
human
microgli
cell
prior
infect
also
result
signific
reduct
veev
titer
suggest
entri
prevent
mechan
inhibit
inde
increas
express
type
interferon
possibl
induc
antivir
state
could
prove
potent
therapeut
candid
veev
possibl
alphavirus
notabl
amp
exhibit
antivir
activ
transferrin
famili
ironbind
protein
lactoferrin
lf
multifunct
kda
glycoprotein
origin
discov
bovin
milk
lf
highli
conserv
found
human
mice
porcin
speci
express
biolog
fluid
exocrin
secret
milk
saliva
fluid
digest
tract
tear
neutrophil
granul
lf
serv
key
compon
innat
immun
defens
demonstr
antimicrobi
activ
wide
rang
bacteria
virus
direct
action
pathogen
membran
target
host
cell
moieti
well
modul
inflamm
tabl
lf
express
may
induc
hormon
control
epitheli
cell
mammari
gland
welldefin
stage
cell
cycl
neutrophil
differenti
lf
structur
consist
polypeptid
chain
character
highli
basic
positivelycharg
ntermin
region
lf
chain
fold
two
globular
lobe
link
threeturn
alpha
helix
lobe
contain
ironbind
site
strong
interact
two
lobe
iron
bound
render
lf
resist
proteolysi
holo
form
compar
open
apo
form
stomach
acid
pepsin
hydrolysi
ntermin
lf
yield
lactoferricin
lfcin
peptid
multipl
hydrophob
positivelycharg
residu
lfcin
retain
properti
lf
demonstr
potent
antivir
activ
earli
studi
demonstr
direct
antirsv
activ
lf
vitro
cell
lf
decreas
product
induc
rsv
infect
preincub
virion
lfmediat
inhibit
depend
lfrsv
interact
lf
inhibit
rsv
entri
cell
preincub
lf
rsv
result
decreas
viral
entri
lf
found
inhibit
rsv
entri
directli
bind
f
subunit
rsv
f
protein
mediat
fusion
virion
cell
membran
human
bovin
lf
demonstr
antiiav
activ
bovin
lf
inhibit
iavmedi
program
cell
death
directli
bind
viral
hemagglutinin
lead
inhibit
viral
hemagglutin
studi
howev
evalu
activ
human
lf
context
iav
infect
madindarbi
canin
kidney
cell
human
lf
demonstr
enhanc
antivir
activ
avian
iav
dosedepend
manner
addit
bovin
lf
inhibit
parainfluenza
viru
replic
vitro
decreas
viral
adsorpt
onto
cell
therebi
prevent
viral
entri
togeth
result
highlight
possibl
role
lf
prevent
influenza
parainfluenza
viru
infect
lactoferrinmedi
antihadv
activ
occur
multipl
stage
infect
one
studi
lf
inhibit
hadv
replic
differ
phase
infect
peptid
introduc
infect
viral
adsorpt
peptid
present
throughout
experi
indic
one
mechan
action
may
involv
bovin
lf
also
demonstr
antihadv
properti
dosedepend
manner
similar
human
lf
bovin
lf
demonstr
greatest
inhibit
viru
preincub
lf
mgml
valid
electron
microscopi
imag
bind
lf
hadv
thu
suggest
direct
lf
inhibit
mechan
action
contrast
human
lf
tear
fluid
implic
promot
hadv
bind
epitheli
cell
wherebi
hadv
hijack
human
lf
util
protein
order
bind
host
cell
studi
assess
inhibit
reveal
potenc
lf
inhibit
replic
virus
lf
mgml
inhibit
replic
human
embryo
lung
cell
prevent
viru
adsorpt
entri
marchetti
et
al
also
demonstr
abil
bovin
human
lf
inhibit
replic
adsorpt
vero
cell
independ
ironbind
furthermor
intracellular
traffick
virion
gain
entri
delay
similar
inhibitori
properti
display
lfcin
peptid
test
addit
celltocel
viral
spread
inhibit
lf
well
lfcin
data
present
studi
demonstr
lf
antivir
properti
hsv
lactoferrin
demonstr
efficaci
hcv
hbv
bovin
lf
prevent
hcv
infect
human
hepatocyt
turn
test
measur
control
hcv
viremia
chronic
hepat
c
patient
howev
lf
reduc
hcv
rna
patient
previous
low
hcv
rna
serum
concentr
convers
random
trial
bovin
lf
patient
chronic
hepat
c
report
orallyadminist
lf
demonstr
signific
efficaci
hcv
compar
placebo
control
combin
therapi
use
antivir
molecul
ribavirin
lf
interferon
therapi
hand
suggest
lf
contribut
decreas
hcv
rna
titer
contradictori
result
suggest
orallyadminist
lf
may
promis
standalon
therapeut
enhanc
effect
current
use
therapeut
studi
interact
hcv
lf
report
direct
interact
bind
human
bovin
lf
hcv
envelop
protein
recent
studi
conclud
lf
variou
speci
directli
prevent
hcv
cell
entri
bind
virion
furthermor
preincub
virion
posttreat
infect
cell
human
bovin
sheep
camel
lf
inhibit
hcv
replic
human
hepatoma
cell
suggest
lf
may
use
prophylact
well
therapeut
particularli
combin
therapi
preincub
hbv
lf
effect
viral
replic
howev
pretreat
cell
human
bovin
lf
prevent
infect
bovin
lf
interact
hbv
indirectli
protect
cell
hbv
infect
addit
iron
zinsatur
lf
hbvinfect
cell
inhibit
hbvdna
amplif
suggest
use
possibl
candid
treatment
hbv
infect
circul
lf
plasma
level
patient
significantli
decreas
compar
noninfect
patient
suggest
import
role
lf
infect
diseas
progress
experi
assess
role
lf
infect
peripher
blood
mononuclear
cell
reveal
lf
ic
potent
inhibitor
six
clinic
isol
dosedepend
manner
upon
treatment
cell
prior
infect
addit
synergist
effect
human
bovin
lf
assess
combin
zidovudin
also
demonstr
dosedepend
inhibit
bovin
lf
inhibit
entri
process
bind
viral
envelop
variant
resist
lf
exhibit
mutat
viral
envelop
protein
bovin
lf
found
potent
inhibitor
human
lf
prevent
dendrit
cellmedi
transmiss
cell
directli
strongli
bind
dcsign
receptor
molecul
dendrit
cell
mediat
intern
pediatr
infect
lf
enhanc
respons
antiretrovir
therapi
decreas
plasma
viral
load
modul
immun
system
lf
treatment
alon
increas
cell
count
signific
increas
observ
lf
combin
antiretrovir
therapi
result
suggest
symptom
evid
durat
experi
howev
largescal
studi
requir
order
assess
lf
therapeut
potenti
hiv
hantaviru
zoonot
rna
viru
caus
sever
human
diseas
character
widespread
extens
hemorrhag
vitro
studi
demonstr
pretreat
vero
cell
lf
ed
significantli
reduc
hantaviru
foci
number
combin
lf
ribavirin
also
significantli
reduc
number
viral
foci
pretreat
cell
lf
treatment
ribavirin
post
infect
complet
abolish
viral
foci
addit
synthesi
viral
glycoprotein
nucleocapsid
protein
np
delay
lf
pretreat
cell
vivo
test
reveal
prophylact
lf
treatment
mgkg
significantli
improv
surviv
rate
follow
hantaviru
infect
suckl
mice
compar
nontreat
mice
human
bovin
lf
lfcin
demonstr
inhibit
intern
particl
visual
use
hpv
viruslik
particl
vlp
fluoresc
cellular
intern
inhibit
occur
dosedepend
manner
hacat
cell
bovin
lfmediat
inhibit
potent
human
lf
howev
lf
inhibit
differ
synthet
deriv
variant
human
bovin
lfcin
demonstr
select
inhibit
hpv
human
variant
lfcin
amino
acid
display
antivir
activ
well
inhibit
attach
hpv
strain
bovin
variant
inhibit
infect
result
suggest
differ
domain
lfcin
contain
select
specif
antivir
properti
engin
target
specif
infect
viral
strain
rotaviru
one
world
major
caus
gastroenter
children
effort
develop
antirotaviru
strategi
milk
protein
includ
apolf
felf
assess
inhibitori
properti
rotaviru
result
demonstr
apolf
potent
inhibitor
rotaviru
bind
viral
particl
hinder
viru
attach
well
prevent
rotaviru
hemagglutin
random
trial
howev
conclud
orallyadminist
lf
provid
protect
rotaviru
infect
serv
exampl
pronounc
inhibit
vitro
necessarili
recapitul
effect
occur
vivo
lactoferrin
antivir
activ
virus
includ
polioviru
alphavirus
denv
japanes
enceph
viru
jev
studi
vero
cell
iron
manganes
zincsatur
lf
demonstr
antipolioviru
properti
dosedepend
manner
lf
present
either
entir
viral
life
cycl
viral
adsorpt
alphavirus
human
lf
inhibit
infect
cell
sindbi
viru
sinv
semliki
forest
virus
sfv
adapt
bind
heparan
sulfat
hs
upon
pretreat
cell
prior
infect
lfmediat
inhibit
thought
occur
bind
lf
heparan
sulfat
moieti
therebi
prevent
virusreceptor
interact
bovin
lf
test
jev
denv
capabl
inhibit
replic
virus
jev
similar
alphavirus
hsadapt
jev
strain
inhibit
bovin
lf
wildtyp
strain
bovin
lf
inhibit
bind
denv
hs
directli
interact
hs
addit
morbid
denvinfect
suckl
mice
reduc
upon
administr
mixtur
denv
lf
compar
denvonlyinfect
mice
eosinophil
contain
larg
cytoplasm
granul
play
critic
role
innat
immun
respons
granul
storag
hotspot
major
cation
antimicrobi
protein
includ
eosinophilderiv
neurotoxin
edn
eosinophil
cation
protein
ecp
edn
ecp
human
antimicrobi
protein
activ
ribonucleas
member
human
rnase
superfamili
antimicrobi
properti
rnase
map
ntermin
domain
conserv
among
ribonucleas
protein
contain
characterist
rnase
superfamili
structur
catalyt
residu
exhibit
antimicrobi
activ
bacteria
virus
tabl
eosinophilderiv
neurotoxin
edn
also
known
rnase
demonstr
inhibitori
activ
rsv
sever
studi
one
studi
rsv
infect
decreas
dosedepend
manner
eosinophil
introduc
suspens
rsv
properti
abolish
upon
addit
ribonucleas
inhibitor
suggest
rnase
respons
antivir
activ
nm
plasmidconstruct
recombin
human
edn
exhibit
reduct
rsv
infect
decreas
rsv
genom
rna
copi
quantifi
rtpcr
upon
incub
edn
virion
suggest
edn
ribonucleas
activ
directli
target
extracellular
viral
particl
edn
may
contain
uniqu
featur
help
mediat
antivir
activ
ribonucleas
alon
effect
rsv
infect
addit
ecp
also
known
rnase
detect
infant
acut
bronchiol
follow
rsv
infect
ecp
level
significantli
higher
infant
develop
persist
wheez
compar
fiveyear
followup
addit
ecp
abl
reduc
rsv
infect
suspens
edn
ecp
less
effect
use
inhibit
rsv
alon
demonstr
sixfold
reduct
compar
edn
concentr
nm
henc
ecp
exhibit
inhibitori
activ
rsv
suffici
control
infect
rsv
infect
induc
product
ecp
evid
antivir
effect
instead
product
ecp
infant
bronchiol
use
tool
predict
risk
wheez
cough
develop
infant
higher
ecp
level
correl
wheez
cough
develop
earlier
studi
edn
demonstr
direct
activ
hiv
howev
indirectli
induc
product
hivinhibit
molecul
solubl
factor
produc
host
chemokin
interferon
rnase
alloantigenstimul
factor
asf
report
inhibit
replic
bind
test
determin
solubl
inhibitori
activ
util
supernat
mix
lymphocyt
healthi
individu
exhibit
activ
supernat
exhibit
antihiv
activ
activ
block
antibodi
specif
edn
antibodi
rnase
effect
activ
thu
rule
involv
addit
rnase
inhibitor
significantli
block
inhibitori
activ
indic
edn
possibl
closelyrel
rnase
respons
inhibitori
activ
later
studi
report
edn
recombin
edn
contain
four
amino
acid
extens
nterminu
end
exhibit
activ
independ
time
addit
h
post
infect
immun
cell
abil
produc
amp
proteas
inhibitor
elafin
secretori
leukocyt
proteas
inhibitor
slpi
studi
investig
amp
produc
gammadelta
cell
cell
record
product
elafin
elafin
express
tissu
skin
placenta
genit
gastrointestin
tract
well
cell
includ
neutrophil
epitheli
cell
macrophag
keratinocyt
thu
found
mani
surfac
secret
elafin
singlepolypeptid
chain
produc
proteolyt
cleavag
precursor
molecul
call
similarli
slpi
express
neutrophil
macrophag
epitheli
cell
renal
tubul
respiratoryalimentari
tract
peptid
found
saliva
cervic
mucu
breast
milk
cerebr
spinal
fluid
tear
secret
nose
bronchi
slpi
cysteinerich
polypeptid
chain
highli
basic
ctermin
elafin
slpi
exhibit
high
homolog
similar
proteas
activ
demonstr
antimicrobi
well
antiinflammatori
activ
tabl
elafin
precursor
tr
exhibit
antihsv
activ
drannik
colleagu
investig
efficaci
elafin
tr
infect
use
trexpress
replicationdefici
adenoviru
vector
well
recombin
trelafin
protein
cell
either
infect
adenoviru
vector
treat
recombin
protein
prior
infect
endometri
endocerv
epitheli
cell
pretreat
molecul
tr
ic
e
ic
viral
titer
follow
infect
significantli
reduc
activ
tr
potent
inhibit
elafin
decreas
viral
titer
correl
decreas
product
proinflammatori
cytokin
wherea
antivir
respons
increas
furthermor
recombin
molecul
decreas
viral
attach
cell
vivo
trtransgen
mice
mice
gener
express
full
elafintr
human
gene
demonstr
reduc
central
nervou
system
viral
load
express
upon
intravagin
infect
data
provid
evid
elafin
precursor
potenti
antihsv
therapeut
proteas
elafin
slpi
provid
protect
vitro
slpi
saliva
demonstr
properti
vitro
genit
secret
femal
hivresist
contain
significantli
higher
level
elafintr
compar
uninfect
femal
addit
elafintr
found
produc
epitheli
cell
uterin
fallopian
tube
cervix
ghosh
et
al
investig
abil
elafintr
reproduct
tract
inhibit
demonstr
inhibit
dosedepend
particularli
preincub
elafintr
ngml
suggest
inhibit
mediat
direct
interact
elafintr
viru
howev
recent
report
multipl
group
hivinfect
women
found
correl
antihiv
activ
mediat
elafin
hiv
suscept
hepcidin
also
known
human
liver
express
antimicrobi
acid
long
amp
predomin
express
liver
hepatocyt
first
isol
human
blood
filtrat
hepcidin
synthes
prepropeptid
two
cleavag
site
first
cleavag
site
releas
ntermin
endoplasm
reticulum
signal
sequenc
second
cleavag
site
releas
matur
hepcidin
peptid
prodomain
hepcidin
play
major
role
iron
regul
system
iron
homeostasi
hepatocyt
cell
hepcidin
regul
iron
uptak
efflux
directli
bind
iron
export
ferroportin
result
degrad
transport
consequ
high
level
hepcidin
result
inhibit
iron
uptak
sequestr
blood
iron
macrophag
wherea
low
level
hepcidin
result
excess
uptak
toxic
accumul
dietari
iron
henc
increas
serum
iron
level
increas
hepcidin
express
vital
role
hepcidin
iron
homeostasi
determin
outcom
infect
limit
iron
avail
invad
pathogen
rel
littl
inform
avail
effect
hepcidin
pathogenesi
viral
infect
howev
hepcidin
induct
report
follow
number
human
murin
viral
infect
hepcidin
mrna
level
significantli
increas
mice
influenza
viru
infect
induct
appear
depend
knockout
mice
induc
express
hepcidin
mrna
addit
primari
hepatocyt
stimul
pathogenassoci
molecular
pattern
pamp
hepcidin
inhibit
addit
neutral
antibodi
result
indic
hepcidin
express
increas
follow
viral
infect
infectioninduc
inflammatori
respons
particularli
due
central
role
cytokin
play
hepcidin
product
liver
injuri
well
chronic
liver
infect
hepat
b
c
result
abnorm
hepcidin
express
hepcidin
express
found
highli
elev
chronic
hepat
b
c
patient
report
wang
colleagu
patient
increas
hbv
dna
hepcidin
level
elev
howev
exact
correl
hepcidin
determin
contrast
studi
assess
hepcidin
level
hbv
hcv
acut
infect
primari
virem
phase
hepcidin
level
upregul
hypoferremia
evid
differ
could
attribut
differ
stage
diseas
hepcidin
may
induc
later
stage
infect
iron
level
elev
studi
armitag
et
al
also
measur
hepcidin
level
posit
plasma
donor
acut
infect
patient
transit
chronic
infect
former
group
hepcidin
level
increas
peak
peak
viral
load
iron
level
decreas
due
retent
cell
hepcidin
activ
wherea
latter
group
hepcidin
level
remain
elev
even
individu
undergo
art
increas
hepcidin
level
coincid
increas
inflammatori
cytokin
express
hiv
replic
irondepend
hepcidininduc
sequest
iron
cell
lymphocyt
macrophag
highli
favor
condit
hiv
pathogenesi
neuropeptid
np
low
molecular
weight
cation
amphipath
amp
tradit
np
thought
transmit
modul
signal
central
peripher
nervou
system
howev
recent
year
np
demonstr
antimicrobi
activ
np
hormon
exhibit
antivir
antiinflammatori
activ
tabl
acid
peptid
product
posttransl
process
precursor
molecul
proopiomelanocortin
pomc
wide
express
peripher
brain
tissu
numer
cell
includ
monocyt
dendrit
cell
melanocyt
pituitari
cell
well
lymphocyt
activ
compon
resid
ctermin
tripeptid
kpv
hivinfect
monocyt
exhibit
inhibitori
properti
previous
inhibit
proinflammatori
cytokin
product
blood
hivinfect
individu
barcellini
et
al
aim
determin
exhibit
antihiv
properti
util
chronic
infect
monocyt
cell
acut
infect
monocytederiv
macrophag
cell
consist
produc
tripeptid
kpv
inhibit
hiv
express
low
concentr
compar
physiolog
concentr
inhibit
pronounc
higher
concentr
addit
peptid
inhibit
nuclear
factorkb
nfkb
activ
known
enhanc
hiv
viral
protein
express
recent
year
antivir
properti
amp
natur
occur
synthet
therapeut
potenti
gener
increas
interest
within
academ
pharmaceut
commun
mani
amp
origin
thought
demonstr
antibacteri
activ
found
exhibit
antivir
immun
modulatori
capabl
date
ampbas
therapi
clinic
approv
far
suitabl
efficaci
amp
therapeut
agent
studi
clinic
trial
treatment
infect
well
agent
immun
modul
clinic
studi
util
amp
includ
defensinmimet
compound
ctix
treatment
drugresist
klebsiella
pneumonia
alphahel
amp
gram
neg
posit
bacteri
skin
infect
cation
peptid
dpk
skin
dermat
amp
promis
therapeut
due
rel
low
toxic
toler
vivo
amp
deliv
varieti
way
includ
intraven
inject
oral
administr
topic
ointment
via
inhal
respiratori
tract
infect
supplement
treatment
amp
defensin
may
provid
protect
lung
exampl
nebul
mice
prior
infect
iav
reduc
diseas
sever
result
increas
surviv
rate
concept
could
appli
respiratori
pathogen
rsv
rhinoviru
inclus
amp
lactoferrin
edn
previous
demonstr
efficaci
rsv
amp
also
appli
ointment
gel
cream
instanc
gel
treatment
vagin
candidiasi
current
clinic
trial
deriv
human
previous
demonstr
antivir
activ
hiv
form
treatment
could
develop
cheap
effect
strategi
reduc
hiv
transmiss
treatment
expand
sexual
transmit
diseas
hsv
includ
mani
class
amp
demonstr
antivir
activ
particular
virus
equal
oral
formul
intraven
inject
feasibl
viral
infect
affect
intern
organ
lactoferrin
use
oral
supplement
antivir
therapi
hcv
infect
greatli
enhanc
effect
treatment
studi
util
oral
lf
pathogen
alon
provid
promis
result
differ
amp
may
prove
effect
differ
pathogen
intraven
treatment
human
lf
current
clinic
trial
treatment
bacteremia
fungal
infect
interestingli
proteas
inhibitor
telaprevir
market
use
hcv
suggest
eosinophil
peptid
dual
function
proteas
inhibitor
amp
may
possess
antihcv
properti
addit
amp
directli
target
virus
serv
altern
antivir
resist
becom
issu
challeng
virus
chang
envelop
lipid
composit
nonetheless
research
investig
requir
assess
full
potenti
amp
novel
therapeut
howev
despit
appeal
sever
success
vitro
outcom
follow
use
amp
antivir
therapeut
greater
applic
therapeut
face
mani
hurdl
littl
clinic
data
use
toxic
efficaci
method
deliveri
host
uptak
vivo
respons
amp
current
avail
guid
develop
amp
therapeut
product
unclear
whether
extent
laboratori
find
translat
antivir
activ
vivo
addit
relationship
peptid
concentr
use
vitro
experi
physiolog
effect
concentr
requir
vivo
activ
unknown
mani
amp
exampl
antibacteri
activ
amp
appear
heavili
depend
environment
condit
use
experi
sever
amp
report
control
group
streptococcu
physiolog
concentr
ineffect
vitro
suggest
partli
due
physiolog
ionic
environ
recapitul
fulli
laboratori
experi
moreov
amp
minim
activ
vitro
assay
shown
effici
control
infect
upon
vivo
administr
highlight
lack
clear
correl
efficaci
dosedepend
amp
deriv
laboratori
experi
anim
model
infect
research
correl
antivir
activ
amp
vitro
translat
activ
vivo
efficaci
need
develop
amp
new
class
therapeut
anoth
import
challeng
isol
larg
scale
manufactur
amp
high
cost
produc
amp
imped
applic
clinic
use
commercialscal
manufactur
platform
yet
exist
complex
secondari
structur
amp
also
serv
obstacl
largescal
product
activ
structurebas
use
express
system
bacteri
system
gener
correctli
fold
peptid
larg
quantiti
howev
peptid
suscept
proteolyt
degrad
system
turn
amp
viabl
therapeut
clinic
use
product
disadvantag
must
overcom
meanwhil
altern
nonhuman
amp
use
exampl
numer
studi
examin
activ
lf
util
bovin
instead
human
lf
due
eas
produc
bovin
lf
bulk
bovin
lf
demonstr
equival
time
enhanc
efficaci
compar
human
form
amp
may
function
similarli
may
contain
sequenc
variat
limit
abolish
properti
synthet
peptid
may
prove
practic
altern
howev
expens
gener
futur
use
therapi
requir
develop
novel
synthesi
method
sever
system
demonstr
promis
massproduct
amp
includ
mammalian
cell
transgen
plant
mammalian
cell
cultur
system
prefer
produc
human
amp
costeffect
plant
bioreactor
howev
costeffect
method
commercialscal
amp
product
demonstr
applic
compound
anoth
interest
approach
could
possibl
counteract
challeng
recent
gain
attent
employ
agent
induc
increas
express
amp
exampl
vitamin
induc
product
use
boost
natur
respons
infect
suggest
use
prior
potenti
denv
outbreak
furthermor
metabol
stabil
amp
may
limit
futur
clinic
applic
lack
data
assess
pharmacokinet
amp
address
issu
physiolog
halflif
peptid
necessari
dose
regiment
aggreg
peptid
vivo
exampl
amp
oral
topic
formul
subject
enzymat
degrad
chang
ph
ionic
concentr
face
hurdl
upon
deliveri
penetr
uptak
skin
intestin
nasal
mucosa
intraven
administ
amp
also
face
proteolyt
degrad
enzym
plasma
tissu
although
rel
shorter
halflif
amp
compar
smallmolecul
drug
may
consid
benefici
context
due
lack
accumul
tissu
addit
amp
sensit
salt
serum
factor
substanti
reduc
activ
limit
applic
clinic
use
deliveri
suffici
amount
amp
infect
site
may
also
present
challeng
requir
care
calibr
dose
exampl
topic
applic
amp
skin
may
requir
largescal
applic
ointment
rais
issu
sensit
develop
allergi
appli
amp
similarli
amp
activ
context
natur
innat
immun
occur
presenc
numer
feedback
pathway
collect
calibr
antipathogen
respons
appropri
level
remain
determin
introduct
potenti
high
dose
amp
infect
interact
pathway
modul
activ
amp
therapeut
especi
synthet
amp
appear
elicit
weaker
immun
respons
upon
administr
compar
respons
produc
natur
secret
peptid
infect
challeng
may
consider
imped
clinic
develop
amp
incorpor
innov
formul
speed
process
bring
amp
product
clinic
phase
use
nanoparticl
np
deliveri
vehicl
may
greatli
improv
metabol
stabil
amp
nanoparticl
provid
uniqu
advantag
protect
amp
proteolyt
degrad
control
rate
peptid
releas
sever
nanoparticl
evalu
deliveri
amp
exampl
selfassembl
hyaluron
acid
ha
nanogel
use
success
deliv
analog
via
intratrach
administr
tuberculosisinfect
mice
addit
ha
nanocarri
abl
stabil
peptid
decreas
peptid
cytotox
macrophag
vitro
poli
lacticcoglycol
acid
pgla
np
also
success
util
deliv
cation
amp
although
formul
investig
experiment
anim
model
vitro
applic
outcom
develop
futur
ampbas
therapeut
appear
promis
progress
made
last
decad
elucid
mechan
action
variou
amp
primari
mechan
ampmedi
antivir
activ
attribut
direct
interfer
destabil
viral
envelop
howev
amp
also
demonstr
select
immun
modul
antivir
activ
envelop
nonenvelop
virus
report
latter
hint
presenc
undiscov
activ
amp
addit
known
direct
interact
viral
envelop
inde
antivir
activ
also
report
post
entri
step
affect
later
stage
viral
life
cycl
genom
replic
viral
protein
traffick
addit
studi
demonstr
amp
treatment
prior
viral
infect
result
peptid
retent
intern
cell
may
reflect
robust
respons
virus
compar
potenti
therapeut
develop
addit
postinfect
treatment
report
exhibit
antivir
activ
howev
lesser
extent
treatment
prior
infect
nonetheless
treatment
play
role
alter
viral
replic
assembl
well
role
acceler
immun
activ
suppress
henc
amp
directli
impact
viral
infect
modul
host
process
ultim
impact
viral
replic
neg
amp
report
drive
interferon
signal
contribut
induct
antivir
state
suscept
cell
dual
function
amp
advantag
use
prophylact
andor
part
postexposur
antivir
measur
vulner
individu
prophylact
express
amp
potenti
becom
prevent
strategi
viral
infect
especi
emerg
pandem
addit
simplic
amp
make
develop
synthet
peptid
analogu
costeffect
measur
treat
establish
viral
infect
amp
synthet
deriv
promis
avenu
yield
new
strategi
control
treat
wide
rang
viral
diseas
applic
still
preliminari
stage
therefor
research
warrant
understand
amp
antivir
activ
vivo
vitro
determin
underli
mechan
involv
ampmedi
immun
modul
clinic
applic
hiv
inhibit
nfkb
cytokin
product
author
fund
work
support
defens
threat
reduct
agenc
author
declar
conflict
interest
